

Immune self-reactivity triggered by drug-modified HLA

Nature

486, 554-558

DOI: [10.1038/nature11147](https://doi.org/10.1038/nature11147)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Drug allergy. Human Vaccines and Immunotherapeutics, 2012, 8, 1513-1524.	1.4	13
2	A false sense of non-self. Nature, 2012, 486, 479-481.	13.7	5
3	Research Highlights: Explanation for <i>HLA-B*57:01</i>-linked immune-mediated abacavir-induced hypersensitivity. Pharmacogenomics, 2012, 13, 1567-1569.	0.6	9
4	Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome. Cell Research, 2012, 22, 1637-1639.	5.7	5
5	HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 2012, 13, 1285-1306.	0.6	161
6	MR1 presents microbial vitamin B metabolites to MAIT cells. Nature, 2012, 491, 717-723.	13.7	1,158
7	Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1338-1346.	2.7	65
8	A structural voyage toward an understanding of the <sc>MHC</sc>â€œrestricted immune response: lessons learned and much to be learned. Immunological Reviews, 2012, 250, 61-81.	2.8	81
9	Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis. Current Opinion in Immunology, 2012, 24, 730-735.	2.4	64
12	Recognition of self and altered self by T cells in autoimmunity and allergy. Protein and Cell, 2013, 4, 8-16.	4.8	36
13	Rash, organ dysfunction, and eosinophiles: it is a DRESS. Intensive Care Medicine, 2013, 39, 1666-1667.	3.9	2
14	Drug Allergy. , 2013, , .		31
15	Monitoring abacavir bioactivation in humans: Screening for an aldehyde metabolite. Toxicology Letters, 2013, 219, 59-64.	0.4	20
17	Major Histocompatibility Complex Genomics and Human Disease. Annual Review of Genomics and Human Genetics, 2013, 14, 301-323.	2.5	580
18	Human leukocyte antigen-associated drug hypersensitivity. Current Opinion in Immunology, 2013, 25, 81-89.	2.4	76
19	The Genetics of Complex Cholestatic Disorders. Gastroenterology, 2013, 144, 1357-1374.	0.6	126
20	T cell recognition of beryllium. Current Opinion in Immunology, 2013, 25, 775-780.	2.4	18
21	Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clinical and Experimental Allergy, 2013, 43, 1246-1255.	1.4	103

#	ARTICLE	IF	CITATIONS
22	Status report from "double agent HLA™: Health and disease. <i>Molecular Immunology</i> , 2013, 55, 2-7.	1.0	15
23	Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 493-495.	1.5	12
24	Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Dermatologica Sinica</i> , 2013, 31, 175-180.	0.2	23
25	A peptide's perspective on antigen presentation to the immune system. <i>Nature Chemical Biology</i> , 2013, 9, 769-775.	3.9	72
26	Pharmacogenomics of adverse drug reactions. <i>Genome Medicine</i> , 2013, 5, 5.	3.6	87
27	Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 153-158.	2.3	199
28	Micro Total Analysis Systems: Fundamental Advances and Applications in the Laboratory, Clinic, and Field. <i>Analytical Chemistry</i> , 2013, 85, 451-472.	3.2	193
29	Drug reaction with eosinophilia and systemic symptoms: A drug-induced hypersensitivity syndrome with variable clinical features. <i>Dermatologica Sinica</i> , 2013, 31, 196-204.	0.2	48
30	Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. <i>Dermatologica Sinica</i> , 2013, 31, 181-190.	0.2	13
31	Adult-onset temporal lobe epilepsy, cognitive decline, multi-antiepileptic drug hypersensitivity, and Hashimoto's encephalopathy: Two case studies. <i>Epilepsy & Behavior Case Reports</i> , 2013, 1, 132-135.	1.5	6
32	Symptoms of atopic dermatitis are influenced by outdoor air pollution. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 495-498.e1.	1.5	157
33	Predisposed " T cell antigen receptor recognition of MHC and MHC-I like molecules?. <i>Current Opinion in Immunology</i> , 2013, 25, 653-659.	2.4	13
34	Rhinovirus colocalizes with CD68- and CD11b-positive macrophages following experimental infection in humans. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 758-761.e3.	1.5	23
35	Targeting the trimolecular complex. <i>Clinical Immunology</i> , 2013, 149, 339-344.	1.4	14
36	HLA-B*57:01+ abacavir-naive individuals have specific T cells but no patch test reactivity. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 756-758.	1.5	22
38	Not all empty MHC class I molecules are molten globules: Tryptophan fluorescence reveals a two-step mechanism of thermal denaturation. <i>Molecular Immunology</i> , 2013, 54, 386-396.	1.0	33
39	T-Cells from HLA-B*57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms. <i>Chemical Research in Toxicology</i> , 2013, 26, 759-766.	1.7	51
40	Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. <i>Science China Life Sciences</i> , 2013, 56, 119-124.	2.3	26

#	ARTICLE	IF	CITATIONS
41	Oxidative Bioactivation of Abacavir in Subcellular Fractions of Human Antigen Presenting Cells. <i>Chemical Research in Toxicology</i> , 2013, 26, 1064-1072.	1.7	12
42	The Role of Pharmacogenomics in Diabetes, HIV Infection, and Pain Management. , 2013, , 247-271.		0
43	Donorâ€™recipient genetic diversity: the role ofâ€™pharmacogenomics in kidney transplantation. <i>Pharmacogenomics</i> , 2013, 14, 1369-1372.	0.6	3
44	Immune Parameters to Consider When Choosing T-Cell Receptors for Therapy. <i>Frontiers in Immunology</i> , 2013, 4, 229.	2.2	9
45	HLA Haplotype Determines Hapten or p-i T Cell Reactivity to Flucloxacillin. <i>Journal of Immunology</i> , 2013, 190, 4956-4964.	0.4	98
46	HLA-B27-mediated protection in HIV and hepatitis C virus infection and pathogenesis in spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 426-433.	2.0	39
47	<i>HLA-B*13:01</i> and the Dapsone Hypersensitivity Syndrome. <i>New England Journal of Medicine</i> , 2013, 369, 1620-1628.	13.9	260
48	Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease. <i>Journal of Experimental Medicine</i> , 2013, 210, 1403-1418.	4.2	57
49	A Possible Molecular Mechanism of Immunomodulatory Activity of Bilirubin. <i>International Journal of Medicinal Chemistry</i> , 2013, 2013, 1-4.	2.2	5
50	Advances in our understanding of drug hypersensitivity. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1200-1201.	1.4	3
51	Synthesis of ximelagatran, melagatran, hydroxymelagatran, and ethylmelagatran in H-3 labeled form. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 334-337.	0.5	15
52	Idiosyncratic Adverse Drug Reactions: Current Concepts. <i>Pharmacological Reviews</i> , 2013, 65, 779-808.	7.1	253
53	Peptideâ€™binding motifs and characteristics for <i>HLA â€™B*13:01</i> molecule. <i>Tissue Antigens</i> , 2013, 81, 442-448.	1.0	9
54	<sc>HLA</sc>â€™<sc>B</sc> alleles associated with severe cutaneous reactions to antiepileptic drugs in <sc>H</sc>an <sc>C</sc>hinese. <i>Epilepsia</i> , 2013, 54, 1307-1314.	2.6	155
55	HLA Peptide Length Preferences Control CD8+T Cell Responses. <i>Journal of Immunology</i> , 2013, 191, 561-571.	0.4	57
56	A molecular basis for the association of the <i>HLA-DRB1</i> locus, citrullination, and rheumatoid arthritis. <i>Journal of Experimental Medicine</i> , 2013, 210, 2569-2582.	4.2	354
57	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <i>Hepatology</i> , 2013, 57, 727-739.	3.6	212
58	Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1904-1907.	0.3	107

#	ARTICLE	IF	CITATIONS
59	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2013, , .	1.5	6
60	Sulfamethoxazole Induces a Switch Mechanism in T Cell Receptors Containing TCRV β 220-1, Altering pHLA Recognition. PLoS ONE, 2013, 8, e76211.	1.1	55
61	<i>In Silico</i> Risk Assessment of HLA-A*02:06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients. Journal of Toxicology, 2013, 2013, 1-6.	1.4	12
62	HLA-A, -B, -C, -DRB1, and -DQB1 Allele Lineages and Haplotype Frequencies among Saudis. Immunology and Immunogenetics Insights, 2014, 6, III.S16769.	1.0	0
63	HLA and the Pharmacogenomics of Drug Hypersensitivity. , 2014, , 437-465.		5
64	Interaction of Small Molecules with Specific Immune Receptors: The p-i Concept and its Consequences. Current Immunology Reviews, 2014, 10, 7-18.	1.2	11
65	HLA and TCR Recognition of Medications in Severe Cutaneous Adverse Reactions. Current Immunology Reviews, 2014, 10, 51-61.	1.2	3
66	Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nature Communications, 2014, 5, 4757.	5.8	153
67	Digging Up the Human Genome: Current Progress in Deciphering Adverse Drug Reactions. BioMed Research International, 2014, 2014, 1-9.	0.9	7
68	Development and partial validation of a mouse model for predicting drug hypersensitivity reactions. Journal of Immunotoxicology, 2014, 11, 141-147.	0.9	10
69	Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports. Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 100.	0.2	4
70	Typages HLA. , 2014, , 227-236.		0
71	Soluble HLA Technology as a Strategy to Evaluate the Impact of HLA Mismatches. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	19
72	Human Leukocyte Antigen Typing Using a Knowledge Base Coupled with a High-Throughput Oligonucleotide Probe Array Analysis. Frontiers in Immunology, 2014, 5, 597.	2.2	3
73	The Beta Cell Immunoepitidome. Vitamins and Hormones, 2014, 95, 115-144.	0.7	8
74	A comprehensive analysis of constitutive naturally processed and presented HLA (Cw4)-specific peptides. Tissue Antigens, 2014, 83, 174-179.	1.0	47
75	Tests for evaluating non-immediate allergic drug reactions. Expert Review of Clinical Immunology, 2014, 10, 1475-1486.	1.3	5
76	Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions. Drug Metabolism Reviews, 2014, 46, 1-18.	1.5	29

#	ARTICLE	IF	CITATIONS
77	<sc>HLA</sc> and disease: guilt by association. International Journal of Immunogenetics, 2014, 41, 1-12.	0.8	54
78	Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides. Nature Communications, 2014, 5, 3600.	5.8	111
79	PharmGKB summary. Pharmacogenetics and Genomics, 2014, 24, 276-282.	0.7	7
80	The study of severe cutaneous drug hypersensitivity reactions from a systems biology perspective. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 301-306.	1.1	6
81	Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01. Journal of Immunology, 2014, 192, 2984-2993.	0.4	136
82	Mutational and Structural Analysis of KIR3DL1 Reveals a Lineage-Defining Allotypic Dimorphism That Impacts Both HLA and Peptide Sensitivity. Journal of Immunology, 2014, 192, 2875-2884.	0.4	48
83	The importance of hapten-protein complex formation in the development of drug allergy. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 293-300.	1.1	49
84	The impact of germline mutations on targeted therapy. Journal of Pathology, 2014, 232, 230-243.	2.1	7
85	Genotyping for Severe Drug Hypersensitivity. Current Allergy and Asthma Reports, 2014, 14, 418.	2.4	35
86	Bioactivation to an aldehyde metabolite-Possible role in the onset of toxicity induced by the anti-HIV drug abacavir. Toxicology Letters, 2014, 224, 416-423.	0.4	23
87	Distinct activation phenotype of a highly conserved novel <sc>HLA</sc>-restricted epitope during dengue virus infection. Immunology, 2014, 141, 27-38.	2.0	22
88	T Lymphocytes as Tools in Diagnostics and Immunotoxicology. Exs, 2014, , .	1.4	2
89	Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review. Veterinary Dermatology, 2014, 25, 406.	0.4	55
90	The versatility of the $\alpha\beta$ T cell antigen receptor. Protein Science, 2014, 23, 260-272.	3.1	20
91	Understanding the structural dynamics of TCR-pMHC interactions. Trends in Immunology, 2014, 35, 604-612.	2.9	54
92	HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
93	HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient. Chemical Research in Toxicology, 2014, 27, 175-177.	1.7	36
94	Structural Basis of Chronic Beryllium Disease: Linking Allergic Hypersensitivity and Autoimmunity. Cell, 2014, 158, 132-142.	13.5	101

#	ARTICLE	IF	CITATIONS
95	Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. <i>Current Opinion in Immunology</i> , 2014, 31, 24-30.	2.4	70
96	Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. <i>Journal of Proteomics</i> , 2014, 109, 240-244.	1.2	63
97	The Cellular Redox Environment Alters Antigen Presentation. <i>Journal of Biological Chemistry</i> , 2014, 289, 27979-27991.	1.6	52
98	Using mass spectrometry to monitor drug induced changes in antigen presentation by the human leukocyte antigen. <i>Clinical and Translational Allergy</i> , 2014, 4, P43.	1.4	0
99	Subangstrom Accuracy in pHLA-I Modeling by Rosetta FlexPepDock Refinement Protocol. <i>Journal of Chemical Information and Modeling</i> , 2014, 54, 2233-2242.	2.5	46
100	The frequency of HLA-B*57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. <i>Human Immunology</i> , 2014, 75, 1092-1096.	1.2	10
101	Antiviral Drug Allergy. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 645-662.	0.7	10
102	In Vitro Diagnosis of Delayed-type Drug Hypersensitivity. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 691-705.	0.7	18
103	Challenges and promises in modeling dermatologic disorders with bioengineered skin. <i>Experimental Biology and Medicine</i> , 2014, 239, 1215-1224.	1.1	16
104	Immediate-type hypersensitivity drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1-13.	1.1	44
105	Abacavir Forms Novel Cross-Linking Abacavir Protein Adducts in Patients. <i>Chemical Research in Toxicology</i> , 2014, 27, 524-535.	1.7	21
106	Human T cells use CD1 and MR1 to recognize lipids and small molecules. <i>Current Opinion in Chemical Biology</i> , 2014, 23, 31-38.	2.8	19
107	Drug-Induced Liver Injury. , 2014, , 467-477.		0
108	Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities. <i>Maturitas</i> , 2014, 78, 245-251.	1.0	64
109	Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 21-33.	2.0	74
110	Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives. <i>Gastroenterology</i> , 2014, 146, 914-928.e1.	0.6	222
111	Antibiotic Allergy. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 489-506.	0.7	34
112	HLA-DRB1*08:02 Is Associated with Bucillamine-Induced Proteinuria in Japanese Rheumatoid Arthritis Patients. <i>Biomarker Insights</i> , 2014, 9, BMI.S13654.	1.0	9

#	ARTICLE	IF	CITATIONS
113	Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis. <i>Seminars in Liver Disease</i> , 2015, 35, 421-431.	1.8	18
116	Clinical Role of Human Leukocyte Antigen in Health and Disease. <i>Scandinavian Journal of Immunology</i> , 2015, 82, 283-306.	1.3	141
117	Selector function of MHC I molecules is determined by protein plasticity. <i>Scientific Reports</i> , 2015, 5, 14928.	1.6	69
118	Genetics of Interstitial Lung Disease: <i>Vol de Nuit</i> (Night Flight). <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2015, 9s1, CCRPM.S23283.	0.5	16
119	Machine Learning Methods for Predicting HLA-Peptide Binding Activity. <i>Bioinformatics and Biology Insights</i> , 2015, 9s3, BBI.S29466.	1.0	68
120	Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis. <i>BMC Bioinformatics</i> , 2015, 16, S9.	1.2	19
121	Pathogenesis and diagnosis of delayed α -type drug hypersensitivity reactions, from bedside to bench and back. <i>Clinical and Translational Allergy</i> , 2015, 5, 31.	1.4	60
122	HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1305-1316.	1.4	12
123	Towards depersonalized abacavir therapy. <i>Aids</i> , 2015, 29, 2385-2395.	1.0	15
124	Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 402-411.	0.7	73
125	Association of HLA-B*5701 Genotypes and Abacavir-Induced Hypersensitivity Reaction: A Systematic Review and Meta-Analysis. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 68.	0.9	40
126	Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals. <i>PLoS ONE</i> , 2015, 10, e0117160.	1.1	73
127	Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. <i>PLoS ONE</i> , 2015, 10, e0124878.	1.1	11
128	Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212566.	0.2	5
129	Cost-efficient multiplex PCR for routine genotyping of up to nine classical HLA loci in a single analytical run of multiple samples by next generation sequencing. <i>BMC Genomics</i> , 2015, 16, 318.	1.2	68
130	\hat{I}^2 TCR-Mediated Recognition: Relevance to Tumor-Antigen Discovery and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 305-312.	1.6	21
131	Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 395-409.	1.5	47
132	Parsing interindividual drug variability: an emerging role for systems pharmacology. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2015, 7, 221-241.	6.6	57

#	ARTICLE	IF	CITATIONS
133	Pathogenesis of drug allergy â€“ current concepts and recent insights. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1376-1383.	1.4	38
134	Characterization of Self-Assembled Monolayers of Peptide Mimotopes of CD20 Antigen and Their Binding with Rituximab. <i>Langmuir</i> , 2015, 31, 13764-13772.	1.6	14
135	Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. <i>International Archives of Allergy and Immunology</i> , 2015, 168, 13-24.	0.9	71
136	Individualized Medicine. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , .	0.6	8
137	Understanding the complexity and malleability of Tâ€“cell recognition. <i>Immunology and Cell Biology</i> , 2015, 93, 433-441.	1.0	44
138	Revisiting the Arthritogenic Peptide Theory: Quantitative Not Qualitative Changes in the Peptide Repertoire of HLAâ€“B27 Allotypes. <i>Arthritis and Rheumatology</i> , 2015, 67, 702-713.	2.9	102
139	HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. <i>Frontiers in Genetics</i> , 2014, 5, 478.	1.1	31
140	Promiscuous T-cell responses to drugs and drug-haptens. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 474-476.e8.	1.5	41
141	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 262-271.e2.	1.5	51
142	Evolving models of the immunopathogenesis of Tâ€“cellâ€“mediated drug allergy: The role of host, pathogens, and drug response. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 219-234.	1.5	185
143	New approaches for predicting T cellâ€“mediated drug reactions: Aâ€“role for inducible and potentially preventable autoimmunity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 252-257.	1.5	15
144	Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 357-368.	1.5	15
145	The Phytotherapeutic Fenugreek as Trigger of Toxic Epidermal Necrolysis. <i>Dermatology</i> , 2015, 231, 99-102.	0.9	10
146	Towards the development of mechanism-based biomarkers to diagnose drug hypersensitivity. <i>Toxicology Research</i> , 2015, 4, 777-795.	0.9	5
147	Genetic Distinctions in Patients With Primary Sclerosing Cholangitis: Immunoglobulin G4 Elevations and HLA Risk. <i>Gastroenterology</i> , 2015, 148, 886-889.	0.6	5
148	Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis. <i>Journal of Human Genetics</i> , 2015, 60, 691-696.	1.1	24
149	A comprehensive analysis of peptides presented by HLAâ€“A1. <i>Tissue Antigens</i> , 2015, 85, 492-496.	1.0	27
150	Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2237-2248.	0.3	104

#	ARTICLE	IF	CITATIONS
151	PharmGKB summary. Pharmacogenetics and Genomics, 2015, 25, 205-221.	0.7	19
152	HLA-B27. Annual Review of Immunology, 2015, 33, 29-48.	9.5	189
153	T Cell Cross-Reactivity between a Highly Immunogenic EBV Epitope and a Self-Peptide Naturally Presented by HLA-B*18:01+ Cells. Journal of Immunology, 2015, 194, 4668-4675.	0.4	14
154	Adversomics: a new paradigm for vaccine safety and design. Expert Review of Vaccines, 2015, 14, 935-947.	2.0	48
155	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. Journal of Allergy and Clinical Immunology, 2015, 136, 236-244.	1.5	80
156	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance. Drug Safety, 2015, 38, 1211-1218.	1.4	12
157	HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions. Biomarkers in Medicine, 2015, 9, 1079-1093.	0.6	7
158	Personalized medicine approaches in epilepsy. Journal of Internal Medicine, 2015, 277, 218-234.	2.7	71
159	T Cell Antigen Receptor Recognition of Antigen-Presenting Molecules. Annual Review of Immunology, 2015, 33, 169-200.	9.5	603
160	T Cell-Mediated Hypersensitivity Reactions to Drugs. Annual Review of Medicine, 2015, 66, 439-454.	5.0	109
161	Structural and energetic insights into the intermolecular interaction among human leukocyte antigens, clinical hypersensitive drugs and antigenic peptides. Molecular Simulation, 2015, 41, 741-751.	0.9	79
162	Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients: investigating the relation between the HLA -B*4403 allele and lamotrigine. European Journal of Clinical Pharmacology, 2015, 71, 35-41.	0.8	25
163	Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Dermatology, 2015, 42, 42-48.	0.6	35
164	Repertoire of Classical MHC Class I and Class II Molecules. , 2016, , 200-208.		1
165	Toxic epidermal necrolysis. F1000Research, 2016, 5, 951.	0.8	19
166	<i>In silico</i> Analysis of Interactions between HLA-B*58:01 and Allopurinol-related Compounds. Chem-Bio Informatics Journal, 2016, 16, 1-4.	0.1	6
167	T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. Asia Pacific Allergy, 2016, 6, 77-89.	0.6	38
168	Novel Concepts for Drug Hypersensitivity Based on the Use of Long-Time Scale Molecular Dynamic Simulation. Journal of Pharmaceutics, 2016, 2016, 1-6.	4.6	2

#	ARTICLE	IF	CITATIONS
169	MHC Genotyping in Human and Nonhuman Species by PCRbased Next-Generation Sequencing. , 0, , .		2
170	HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. Yonsei Medical Journal, 2016, 57, 118.	0.9	51
171	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. International Journal of Molecular Sciences, 2016, 17, 1714.	1.8	73
172	Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation. International Journal of Molecular Sciences, 2016, 17, 1890.	1.8	39
173	Pharmacogenetics and Pharmacogenomics. , 2016, , 121-137.		5
174	Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*15:02. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 147.	0.9	8
175	Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy, Asthma and Immunology Research, 2016, 8, 3.	1.1	52
176	HLA-DRB1*16. Pharmacogenetics and Genomics, 2016, 26, 218-224.	0.7	63
177	Deciphering the clinical relevance of allo-human leukocyte antigen cross-reactivity in mediating alloimmunity following transplantation. Current Opinion in Organ Transplantation, 2016, 21, 29-39.	0.8	15
178	A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw069.	1.4	24
179	Toxic epidermal necrolysis: The past, the guidelines and challenges for the future. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, 733-735.	0.5	4
180	A pharmacist's role in the individualization of treatment of HIV patients. Personalized Medicine, 2016, 13, 169-188.	0.8	0
181	Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. International Archives of Allergy and Immunology, 2016, 171, 166-179.	0.9	119
182	sNebula, a network-based algorithm to predict binding between human leukocyte antigens and peptides. Scientific Reports, 2016, 6, 32115.	1.6	34
183	Drug-Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization. Chemical Research in Toxicology, 2016, 29, 2040-2057.	1.7	35
185	Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians. Immunology and Cell Biology, 2016, 94, 367-377.	1.0	38
186	Interplay of innate and adaptive immunity in metal-induced hypersensitivity. Current Opinion in Immunology, 2016, 42, 25-30.	2.4	58
187	Characterization of the Antigen Processing Machinery and Endogenous Peptide Presentation of a Bat MHC Class I Molecule. Journal of Immunology, 2016, 196, 4468-4476.	0.4	30

#	ARTICLE	IF	CITATIONS
188	The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1165-1170.	1.1	13
189	Mass Spectrometric and Functional Aspects of Drug-Protein Conjugation. <i>Chemical Research in Toxicology</i> , 2016, 29, 1912-1935.	1.7	48
190	Classifying ADRs – does dose matter?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 10-12.	1.1	27
191	Toxic epidermal necrolysis: the past, the guidelines and challenges for the future. <i>British Journal of Dermatology</i> , 2016, 174, 1171-1173.	1.4	5
192	CD1a on Langerhans cells controls inflammatory skin disease. <i>Nature Immunology</i> , 2016, 17, 1159-1166.	7.0	134
193	HLA and Delayed Drug-Induced Hypersensitivity. <i>International Archives of Allergy and Immunology</i> , 2016, 170, 163-179.	0.9	35
194	The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. <i>Vaccine</i> , 2016, 34, 5251-5261.	1.7	28
195	MHC class II complexes sample intermediate states along the peptide exchange pathway. <i>Nature Communications</i> , 2016, 7, 13224.	5.8	40
196	A Review of the Pathogenesis of Toxic Epidermal Necrolysis. <i>Journal of Nippon Medical School</i> , 2016, 83, 216-222.	0.3	19
197	HLA-A*02 alleles are associated with tetanus antitoxin-induced exanthematous drug eruptions in Chinese patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 538-546.	0.7	7
198	Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 561-576.	1.3	15
199	Allotype specific interactions of drugs and HLA molecules in hypersensitivity reactions. <i>Current Opinion in Immunology</i> , 2016, 42, 31-40.	2.4	47
200	Mismatch in epitope specificities between IFN γ inflamed and uninfamed conditions leads to escape from T lymphocyte killing in melanoma. , 2016, 4, 10.		35
201	Improving drug safety with a systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 94, 84-92.	1.9	22
202	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alpha herpesviruses. <i>Journal of Immunology</i> , 2016, 196, 2205-2218.	0.4	55
203	Adverse cutaneous drug eruptions: current understanding. <i>Seminars in Immunopathology</i> , 2016, 38, 75-86.	2.8	112
204	HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1371-1377.	3.2	80
205	Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite-derived phospholipase. <i>Science Translational Medicine</i> , 2016, 8, 325ra18.	5.8	77

#	ARTICLE	IF	CITATIONS
206	Adverse drug reactions and organ damage: The liver. <i>European Journal of Internal Medicine</i> , 2016, 28, 9-16.	1.0	74
207	Variations in MHC Class II Antigen Processing and Presentation in Health and Disease. <i>Annual Review of Immunology</i> , 2016, 34, 265-297.	9.5	218
208	Reactive Metabolites: Current and Emerging Risk and Hazard Assessments. <i>Chemical Research in Toxicology</i> , 2016, 29, 505-533.	1.7	114
209	A Systems Approach to Understand Antigen Presentation and the Immune Response. <i>Methods in Molecular Biology</i> , 2016, 1394, 189-209.	0.4	27
211	Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation. <i>Journal of Immunology</i> , 2016, 196, 22-27.	0.4	48
212	Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2016, 34, 1806-1817.	2.0	103
213	Using GWAS to identify genetic predisposition in hepatic autoimmunity. <i>Journal of Autoimmunity</i> , 2016, 66, 25-39.	3.0	94
214	HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. <i>Pharmacogenomics Journal</i> , 2016, 16, 83-87.	0.9	50
215	Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. <i>International Journal of Immunogenetics</i> , 2017, 44, 7-26.	0.8	10
216	Molecular challenges imposed by MHC-I restricted long epitopes on T cell immunity. <i>Biological Chemistry</i> , 2017, 398, 1027-1036.	1.2	45
217	Potent NLRP3 Inflammasome Activation by the HIV Reverse Transcriptase Inhibitor Abacavir. <i>Journal of Biological Chemistry</i> , 2017, 292, 2805-2814.	1.6	35
218	Precision medicine in allergic disease—food allergy, drug allergy, and anaphylaxis—document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1006-1021.	2.7	143
219	MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 387-394.	3.6	83
220	Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study. <i>Journal of Cheminformatics</i> , 2017, 9, 13.	2.8	44
221	Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. <i>Nature Immunology</i> , 2017, 18, 402-411.	7.0	175
222	Drug-Induced Cholestasis: Mechanisms and Importance. , 2017, , 117-128.		0
223	Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. <i>Clinical Infectious Diseases</i> , 2017, 64, 1198-1203.	2.9	27
224	Definition of the Nature and Hapten Threshold of the β -Lactam Antigen Required for T Cell Activation In Vitro and in Patients. <i>Journal of Immunology</i> , 2017, 198, 4217-4227.	0.4	54

#	ARTICLE	IF	CITATIONS
225	HLA class I binding prediction via convolutional neural networks. <i>Bioinformatics</i> , 2017, 33, 2658-2665.	1.8	99
226	MAIT cells and MR1-antigen recognition. <i>Current Opinion in Immunology</i> , 2017, 46, 66-74.	2.4	67
227	Severe cutaneous adverse reactions to drugs. <i>Lancet, The</i> , 2017, 390, 1996-2011.	6.3	293
228	HLA Amino Acid Polymorphisms and Kidney Allograft Survival. <i>Transplantation</i> , 2017, 101, e170-e177.	0.5	23
229	Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. <i>Nature</i> , 2017, 545, 243-247.	13.7	181
230	Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease. <i>Digestive Diseases</i> , 2017, 35, 323-333.	0.8	7
231	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 547-563.	2.0	106
232	Contact sensitizers trigger human CD11c autoreactive T cell responses. <i>European Journal of Immunology</i> , 2017, 47, 1171-1180.	1.6	27
233	Human leukocyte antigen and idiosyncratic adverse drug reactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, 21-30.	1.1	32
234	Rational Tuning of Visual Cycle Modulator Pharmacodynamics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 131-145.	1.3	19
235	Evidence for a higher resolution of HLA genotyping by a new NGS-based approach. <i>Transfusion Clinique Et Biologique</i> , 2017, 24, 120-123.	0.2	6
236	Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*5701 allele in a Portuguese HIV-positive population. <i>Porto Biomedical Journal</i> , 2017, 2, 59-62.	0.4	7
237	Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening. <i>Critical Reviews in Toxicology</i> , 2017, 47, 422-439.	1.9	10
238	Multiple Drug Hypersensitivity. <i>International Archives of Allergy and Immunology</i> , 2017, 172, 129-138.	0.9	67
239	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. <i>Journal of Hepatology</i> , 2017, 67, 137-144.	1.8	100
240	Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 86-97.	2.3	32
241	New insights into the understanding of MHC associations with immune-mediated disorders. <i>Hla</i> , 2017, 89, 3-13.	0.4	9
242	Genomics of Adverse Drug Reactions. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 100-109.	4.0	53

#	ARTICLE	IF	CITATIONS
243	Building proteomic tool boxes to monitor MHC class I and class II peptides. <i>Proteomics</i> , 2017, 17, 1600061.	1.3	29
244	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017, 152, 1078-1089.	0.6	174
245	Severe Delayed Drug Reactions. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 785-815.	0.7	27
246	Dapsone and Nitroso Dapsone Activation of Naïve T-Cells from Healthy Donors. <i>Chemical Research in Toxicology</i> , 2017, 30, 2174-2186.	1.7	18
247	The 3 Cs of Antibiotic Allergy—Classification, Cross-Reactivity, and Collaboration. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1532-1542.	2.0	60
248	High Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers among HIV-Infected Patients in Serbia. <i>Intervirology</i> , 2017, 60, 43-47.	1.2	0
249	A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. <i>Journal of Dermatological Science</i> , 2017, 88, 320-329.	1.0	29
250	The molecular basis for peptide repertoire selection in the human leukocyte antigen (HLA) C*06:02 molecule. <i>Journal of Biological Chemistry</i> , 2017, 292, 17203-17215.	1.6	34
251	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. <i>Scientific Reports</i> , 2017, 7, 8653.	1.6	41
252	Development of HLA-B*57:01 Genotyping Real-Time PCR with Optimized Hydrolysis Probe Design. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 742-754.	1.2	7
253	Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population. <i>Epilepsy & Behavior Case Reports</i> , 2017, 8, 108-110.	1.5	14
254	Dual non-contiguous peptide occupancy of HLA class I evoke antiviral human CD8 T cell response and form neo-epitopes with self-antigens. <i>Scientific Reports</i> , 2017, 7, 5072.	1.6	7
255	Of self-lipids, CD1-restricted T cells, and contact sensitization. <i>European Journal of Immunology</i> , 2017, 47, 1119-1122.	1.6	1
256	Molecules, Systems and Signaling in Liver Injury. , 2017, , .		0
257	HLA-B*57. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 81-82.	0.7	0
258	The Critical Role of Mitochondria in Drug-Induced Liver Injury. , 2017, , 159-181.		2
259	Introduction: MHC/KIR and governance of specificity. <i>Immunogenetics</i> , 2017, 69, 481-488.	1.2	18
260	The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions. <i>Immunogenetics</i> , 2017, 69, 617-630.	1.2	63

#	ARTICLE	IF	CITATIONS
261	The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct V β 2 Receptors. <i>Journal of Immunology</i> , 2017, 199, 1223-1237.	0.4	41
262	HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. <i>BMC Infectious Diseases</i> , 2017, 17, 256.	1.3	25
263	How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction. <i>Chemical Research in Toxicology</i> , 2017, 30, 295-314.	1.7	109
264	Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity. <i>Drug Metabolism and Pharmacokinetics</i> , 2017, 32, 31-39.	1.1	14
265	New Approaches to Investigate Drug-Induced Hypersensitivity. <i>Chemical Research in Toxicology</i> , 2017, 30, 239-259.	1.7	18
266	Comparative genomics of the human, macaque and mouse major histocompatibility complex. <i>Immunology</i> , 2017, 150, 127-138.	2.0	84
267	Drug-specific CD4 ⁺ T α 1 cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. <i>British Journal of Dermatology</i> , 2017, 176, 378-386.	1.4	42
269	Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 1576-1580.	0.6	15
270	HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. <i>Frontiers in Pharmacology</i> , 2017, 8, 90.	1.6	32
271	Pathogenesis of Idiosyncratic Drug Induced Liver Injury. , 2017, , 87-100.		3
272	The HLA-A*31:01 allele: influence on carbamazepine treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 29-38.	0.4	31
273	In Silico and In Vitro Analysis of Interaction between Ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01. <i>International Journal of Molecular Sciences</i> , 2017, 18, 694.	1.8	9
274	Structural Elements Recognized by Abacavir-Induced T Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1464.	1.8	21
275	Proofreading of Peptide-MHC Complexes through Dynamic Multivalent Interactions. <i>Frontiers in Immunology</i> , 2017, 8, 65.	2.2	58
276	HLA Class I or Class II and Disease Association: Catch the Difference If You Can. <i>Frontiers in Immunology</i> , 2017, 8, 1475.	2.2	19
277	New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology. <i>Frontiers in Medicine</i> , 2017, 4, 179.	1.2	39
278	Physiology and Pathology of Drug Hypersensitivity: Role of Human Leukocyte Antigens. , 0, , .		4
279	PharmGKB: A worldwide resource for pharmacogenomic information. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2018, 10, e1417.	6.6	205

#	ARTICLE	IF	CITATIONS
280	Generalists and Specialists: A New View of How MHC Class I Molecules Fight Infectious Pathogens. <i>Trends in Immunology</i> , 2018, 39, 367-379.	2.9	108
281	Implications of HLA-allele associations for the study of type IV drug hypersensitivity reactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 261-274.	1.5	2
282	Immunologic Effects of Beryllium Exposure. <i>Annals of the American Thoracic Society</i> , 2018, 15, S81-S85.	1.5	24
283	Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Call for Optimum Patient Stratification and Therapeutics via Pharmacogenomics. <i>Annual Review of Genomics and Human Genetics</i> , 2018, 19, 329-353.	2.5	29
284	The HLA-A*30:02~C*18:02~B*57:03 African haplotype identified with the deletion of the HLA-DRB1 gene in individuals from La Réunion Island. <i>Hla</i> , 2018, 91, 289-291.	0.4	0
285	Vancomycin Mediates IgA Autoreactivity in Drug-Induced Linear IgA Bullous Dermatitis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1473-1480.	0.3	32
286	Identification of Native and Posttranslationally Modified HLA-B*57:01-Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. <i>Proteomics</i> , 2018, 18, e1700253.	1.3	23
287	The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. <i>Journal of Biological Chemistry</i> , 2018, 293, 3236-3251.	1.6	73
289	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
290	Immune drug-induced liver disease and drugs. <i>Current Opinion in Toxicology</i> , 2018, 10, 46-53.	2.6	8
291	An Animal Model of Abacavir-Induced HLA-Mediated Liver Injury. <i>Toxicological Sciences</i> , 2018, 162, 713-723.	1.4	24
292	Operational Experience of an Open-Access, Subscription-Based Mass Spectrometry and Proteomics Facility. <i>Journal of the American Society for Mass Spectrometry</i> , 2018, 29, 439-446.	1.2	3
293	Association between HLA-B*44:03-HLA-C*07:01 haplotype and cold medicine-related Stevens-Johnson syndrome with severe ocular complications in Thailand. <i>British Journal of Ophthalmology</i> , 2018, 102, 1303-1307.	2.1	30
294	The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1546-1554.	0.3	54
295	Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 3-18.	0.1	11
296	Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 297-314.	1.6	15
297	Synergetically understanding the interaction between nano/microspheres and peptide for controllable drug loading via experimental and theoretical approaches. <i>Materials Science and Engineering C</i> , 2018, 83, 169-176.	3.8	14
298	Immune Mechanisms of Drug Allergy. , 2018, , 27-38.		0

#	ARTICLE	IF	CITATIONS
299	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
300	Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. Clinical and Translational Science, 2018, 11, 112-122.	1.5	36
301	HLAs: Key regulators of T-cell-mediated drug hypersensitivity. Hla, 2018, 91, 3-16.	0.4	72
302	Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments. AAPS Journal, 2018, 20, 4.	2.2	106
303	Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 247-292.	9.6	107
304	Evaluation of immune-mediated idiosyncratic drug toxicity using chimeric HLA transgenic mice. Archives of Toxicology, 2018, 92, 1177-1188.	1.9	19
305	Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. Clinical Pharmacology and Therapeutics, 2018, 103, 843-853.	2.3	18
306	Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. Pharmacogenomics Journal, 2018, 18, 480-486.	0.9	17
307	Association between HLA-B*46:01 and cutaneous adverse drug reactions in Han Chinese. Journal of Bio-X Research, 2018, 1, 73-78.	0.3	1
308	Human Leukocyte Antigen Associations in Drug Hypersensitivity Reactions. Clinics in Laboratory Medicine, 2018, 38, 669-677.	0.7	14
309	HLA-B57 micropolymorphism defines the sequence and conformational breadth of the immunopeptidome. Nature Communications, 2018, 9, 4693.	5.8	31
310	A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands. Science Immunology, 2018, 3, .	5.6	142
311	Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B*15:02. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	19
312	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. Chemical Research in Toxicology, 2018, 31, 1022-1024.	1.7	9
313	HLA and kidney disease: from associations to mechanisms. Nature Reviews Nephrology, 2018, 14, 636-655.	4.1	55
314	Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. Journal of Hepatology, 2018, 69, 948-957.	1.8	62
315	Mechanisms leading to T-cell activation in drug hypersensitivity. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 317-324.	1.1	25
316	Recent Advances in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	44

#	ARTICLE	IF	CITATIONS
317	An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. <i>Journal of Immunology Research</i> , 2018, 2018, 1-22.	0.9	111
318	Immunopeptidomics Special Issue. <i>Proteomics</i> , 2018, 18, e1800145.	1.3	5
319	Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows. <i>Frontiers in Immunology</i> , 2018, 9, 912.	2.2	40
320	Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1660.	1.8	8
321	Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking. <i>Journal of Cheminformatics</i> , 2018, 10, 3.	2.8	4
322	Idiosyncratic Adverse Drug Reactions. , 2018, , 681-716.		4
323	Hypersensitivity Reactions to Antiepileptic Drugs in Children: Epidemiologic, Pathogenetic, Clinical, and Diagnostic Aspects. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1879-1891.e1.	2.0	21
324	Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions. <i>Molecular Immunology</i> , 2018, 101, 488-499.	1.0	14
325	Improvement in HLA genotyping by new sequence-specific oligonucleotides kits for HLA-A, -B, and -DRB1 loci. <i>Hla</i> , 2018, 92, 279-287.	0.4	78
326	Pharmacogenetics of Adverse Drug Reactions. <i>Advances in Pharmacology</i> , 2018, 83, 155-190.	1.2	32
327	Genetic and nongenetic factors that may predispose individuals to allergic drug reactions. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 325-332.	1.1	11
328	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 463-486.	4.2	42
329	Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 22-25.	2.3	3
330	Genetic and Environmental Risk Factors for Autoimmune Hepatitis. <i>Clinical Liver Disease</i> , 2019, 14, 29-32.	1.0	11
331	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. <i>Nature Communications</i> , 2019, 10, 3569.	5.8	83
332	Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment. <i>Sensors</i> , 2019, 19, 3543.	2.1	2
333	Clinical Usefulness of HLA-B*58:01 Genotyping in Gouty Arthritis. <i>Journal of Clinical Rheumatology and Immunology</i> , 2019, 19, 27-33.	0.4	2
334	The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome. <i>Scientific Reports</i> , 2019, 9, 10523.	1.6	6

#	ARTICLE	IF	CITATIONS
335	Virus-specific T-cell clonotypes might contribute to drug hypersensitivity reactions through heterologous immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 608-611.e4.	1.5	22
336	HLA Polymorphisms And TKI-Induced Liver Injury in Patients with Cancer: A Meta-analysis. <i>Journal of Cancer</i> , 2019, 10, 2161-2168.	1.2	3
337	The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity. <i>Pharmaceutics</i> , 2019, 11, 536.	2.0	12
338	Structural Immunology. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	4
339	Exhaustive Repertoire of Druggable Cavities at Protein-Protein Interfaces of Known Three-Dimensional Structure. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9732-9742.	2.9	17
340	De novo generation of a functional human thymus from induced pluripotent stem cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1416-1419.e7.	1.5	26
341	Identification of HLA-A*02:06:01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing. <i>Scientific Reports</i> , 2019, 9, 16240.	1.6	16
342	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1413-1416.e7.	1.5	19
343	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 245-253.	2.3	58
344	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. , 2019, 197, 122-152.		83
345	Pharmacogenomics as a Tool for Management of Drug Hypersensitivity Reactions. <i>Current Treatment Options in Allergy</i> , 2019, 6, 1-17.	0.9	1
346	Long Noncoding RNA HCP5, a Hybrid HLA Class I Endogenous Retroviral Gene: Structure, Expression, and Disease Associations. <i>Cells</i> , 2019, 8, 480.	1.8	60
347	HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?. <i>Frontiers in Neurology</i> , 2019, 10, 614.	1.1	3
348	Susceptibility to adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2205-2212.	1.1	24
349	Drug-induced alloreactivity: A new paradigm for allorecognition. <i>American Journal of Transplantation</i> , 2019, 19, 2606-2613.	2.6	8
350	Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. <i>Nature Protocols</i> , 2019, 14, 1687-1707.	5.5	230
351	An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides. <i>Bioconjugate Chemistry</i> , 2019, 30, 1711-1723.	1.8	13
352	Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. <i>Drug Safety</i> , 2019, 42, 973-992.	1.4	66

#	ARTICLE	IF	CITATIONS
353	Allergic reactions to small-molecule drugs: Will we move from reaction to prediction?. American Journal of Health-System Pharmacy, 2019, 76, 574-580.	0.5	2
354	HLA-associated antiepileptic drug-induced cutaneous adverse reactions. Hla, 2019, 93, 417-435.	0.4	52
355	Dapsone and nitroso dapsone-specific activation of T cells from hypersensitive patients expressing the risk allele HLA-B*13:01. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1533-1548.	2.7	37
356	Immune pathomechanism and classification of drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1457-1471.	2.7	131
357	Beta-lactam-induced severe neutropenia: a descriptive study. Fundamental and Clinical Pharmacology, 2019, 33, 223-224.	1.0	3
358	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. Journal of Allergy and Clinical Immunology, 2019, 144, 183-192.	1.5	118
359	Molecular docking predictions of fragrance binding to human leukocyte antigen molecules. Contact Dermatitis, 2019, 81, 174-183.	0.8	5
360	<i>HLA-B*57:01</i> confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2227-2230.	2.7	51
361	Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients. Anais Brasileiros De Dermatologia, 2019, 94, 17-23.	0.5	8
362	Purification, Crystallization and Crystallographic Analysis of HLA-B*15:02 Complexed with an Endogenous Peptide. Crystallography Reports, 2019, 64, 1122-1125.	0.1	1
363	Genetic testing for prevention of severe drug-induced skin rash. The Cochrane Library, 2019, 7, CD010891.	1.5	7
364	Crystal structure of suboptimal viral fragments of Epstein Barr Virus Rta peptide-HLA complex that stimulate CD8 T cell response. Scientific Reports, 2019, 9, 16660.	1.6	1
365	Rationally designed small molecules to prevent type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 90-95.	1.2	5
366	Role of T cells in non-immediate drug allergy reactions. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 294-301.	1.1	3
368	Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system. Pharmacogenetics and Genomics, 2019, 29, 192-199.	0.7	33
369	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	1.5	144
370	Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. , 2019, , .		6
371	Immunology of Cutaneous Adverse Drug Reactions. , 2019, , 23-37.		0

#	ARTICLE	IF	CITATIONS
372	Application of the immunoregulatory receptor LILRB1 as a crystallisation chaperone for human class I MHC complexes. <i>Journal of Immunological Methods</i> , 2019, 464, 47-56.	0.6	1
373	Pharmacogenomics and Cutaneous Adverse Drug Reactions. , 2019, , 39-53.		0
374	The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. <i>Journal of Immunotoxicology</i> , 2019, 16, 1-12.	0.9	20
375	Structure-based selection of human metabolite binding P4 pocket of DRB1*15:01 and DRB1*15:03, with implications for multiple sclerosis. <i>Genes and Immunity</i> , 2019, 20, 46-55.	2.2	8
376	T-Cell Activation by Low Molecular Weight Drugs and Factors That Influence Susceptibility to Drug Hypersensitivity. <i>Chemical Research in Toxicology</i> , 2020, 33, 77-94.	1.7	9
377	Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury. <i>Chemical Research in Toxicology</i> , 2020, 33, 61-76.	1.7	17
378	Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA*57:01 binding and T cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 636-647.	2.7	19
379	HLA*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1170-1178.	2.3	13
380	Drug-induced skin toxicity: gaps in preclinical testing cascade as opportunities for complex in vitro models and assays. <i>Lab on A Chip</i> , 2020, 20, 199-214.	3.1	28
381	Genetic Predisposition to Drug-Induced Liver Injury. <i>Clinics in Liver Disease</i> , 2020, 24, 11-23.	1.0	21
382	The Utility of T-Cell Clonality in Differential Diagnostics of Acute Graft-versus-Host Disease from Drug Hypersensitivity Reaction. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1282-1285.	0.3	6
383	Immune dysregulation increases the incidence of delayed-type drug hypersensitivity reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 781-797.	2.7	21
384	Research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen. <i>International Immunopharmacology</i> , 2020, 81, 106037.	1.7	4
385	Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients. <i>Microbiology and Immunology</i> , 2020, 64, 210-218.	0.7	2
386	Human T cell response to CD1a and contact dermatitis allergens in botanical extracts and commercial skin care products. <i>Science Immunology</i> , 2020, 5, .	5.6	42
387	Pharmacogenomics of Drug-Induced Liver Injury. <i>Advances in Molecular Pathology</i> , 2020, 3, 107-115.	0.2	3
388	Unconventional Peptide Presentation by Classical MHC Class I and Implications for T and NK Cell Activation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7561.	1.8	6
389	High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis. <i>Frontiers in Genetics</i> , 2020, 11, 951.	1.1	4

#	ARTICLE	IF	CITATIONS
390	FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. <i>Non-coding RNA</i> , 2020, 6, 41.	1.3	34
391	Association of HLA polymorphisms and acetaminophen-related Steven-Johnson syndrome with severe ocular complications in Thai population. <i>British Journal of Ophthalmology</i> , 2022, 106, 884-888.	2.1	7
392	Detailed and atypical HLA peptide binding motifs revealed by a novel peptide exchange binding assay. <i>European Journal of Immunology</i> , 2020, 50, 2075-2091.	1.6	24
393	Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. <i>Frontiers in Pharmacology</i> , 2020, 11, 969.	1.6	38
394	Identification of Flucloxacillin-Haptenated HLA-B*57:01 Ligands: Evidence of Antigen Processing and Presentation. <i>Toxicological Sciences</i> , 2020, 177, 454-465.	1.4	21
395	Genetic Susceptibility to Clozapine-Induced Agranulocytosis/Neutropenia Across Ethnicities: Results From a New Cohort of Turkish and Other Caucasian Participants, and Meta-Analysis. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	7
396	Abacavir adverse reactions related with HLA-B*57:01 haplotype in a large cohort of patients infected with HIV. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 167-174.	0.7	2
397	Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1322-1334.	1.6	45
398	The Impact of the "Mis-Peptidome"™ on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9608.	1.8	22
399	New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. <i>Human Immunology</i> , 2020, 81, 300-304.	1.2	19
400	The molecular basis of how buried human leukocyte antigen polymorphism modulates natural killer cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11636-11647.	3.3	16
401	Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. <i>Human Immunology</i> , 2020, 81, 354-360.	1.2	13
402	In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies. <i>Molecular Immunology</i> , 2020, 123, 7-17.	1.0	18
403	Hypersensitivities following allergen antigen recognition by unconventional T cells. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2477-2490.	2.7	13
404	Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 373-387.	1.3	20
405	Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1957-1971.	1.3	25
406	Preferential HLA-B27 Allorecognition Displayed by Multiple Cross-Reactive Antiviral CD8+ T Cell Receptors. <i>Frontiers in Immunology</i> , 2020, 11, 248.	2.2	7
407	Mechanistic insights into antiretroviral drug-induced liver injury. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00598.	1.1	14

#	ARTICLE	IF	CITATIONS
408	Detection of Abacavir-Induced Structural Alterations in Human Leukocyte Antigen-B*57:01 Using Phage Display. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1007-1015.	0.6	9
409	How Mechanism Knowledge Can Help to Management of Drug Hypersensitivity. <i>Current Treatment Options in Allergy</i> , 2020, 7, 14-31.	0.9	0
410	Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6436-6461.	2.9	34
411	Informatics investigations into anti-thyroid drug induced agranulocytosis associated with multiple HLA-B alleles. <i>PLoS ONE</i> , 2020, 15, e0220754.	1.1	3
413	Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. <i>Nature Medicine</i> , 2020, 26, 236-243.	15.2	107
414	Current perspective of the etiopathogenesis of delayed-type, and T-cell-mediated drug-related skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1142-1144.	1.5	8
415	The complexity of T cell-mediated penicillin hypersensitivity reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 150-167.	2.7	11
416	Dynamic cytokine profiles combined with enzyme-linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 814-816.	0.6	5
417	Risk and Association of HLA Alleles with Methimazole-Induced Cutaneous Adverse Reactions in Chinese Han Population. <i>Journal of Investigative Dermatology</i> , 2021, 141, 437-440.	0.3	2
418	HLA-B*39:01:01 is a novel risk factor for antithyroid drug-induced agranulocytosis in Japanese population. <i>Pharmacogenomics Journal</i> , 2021, 21, 94-101.	0.9	4
419	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 153-169.	1.5	22
420	Drug-specific T cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1825-1835.	2.7	12
421	A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. <i>Toxicological Research</i> , 2021, 37, 1-23.	1.1	68
422	Anthem: a user customised tool for fast and accurate prediction of binding between peptides and HLA class I molecules. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	37
423	Genetic Variants Associated With Drug-Induced Hypersensitivity Reactions: towards Precision Medicine?. <i>Current Treatment Options in Allergy</i> , 2021, 8, 42-59.	0.9	0
424	An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity. <i>Frontiers in Pharmacology</i> , 2020, 11, 573573.	1.6	32
425	Drug Reaction with Eosinophilia and Systemic Symptoms: A Complex Interplay between Drug, T Cells, and Herpesviridae. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1127.	1.8	7
426	Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS). <i>International Journal of Molecular Sciences</i> , 2021, 22, 2147.	1.8	49

#	ARTICLE	IF	CITATIONS
427	Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides. <i>Frontiers in Immunology</i> , 2020, 11, 629399.	2.2	16
428	Familial drug reaction with eosinophilia and systemic symptoms syndrome. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 383-385.	0.2	1
431	Massive clonal expansion of polyclonal skin and blood CD8 ⁺ T cells in patients with toxic epidermal necrolysis. <i>Science Advances</i> , 2021, 7, .	4.7	20
432	Model Based Evaluation of Hypersensitivity Adverse Drug Reactions to Antimicrobial Agents in Children. <i>Frontiers in Pharmacology</i> , 2021, 12, 638881.	1.6	3
433	IFN γ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation. <i>Frontiers in Immunology</i> , 2021, 12, 645770.	2.2	25
434	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557.	1.8	34
435	Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2594-2599.	1.1	4
436	Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition. <i>Frontiers in Immunology</i> , 2021, 12, 653710.	2.2	14
437	In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 630530.	2.2	13
438	Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 588063.	1.6	13
439	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. <i>Frontiers in Immunology</i> , 2021, 12, 658593.	2.2	14
440	Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions. <i>Frontiers in Genetics</i> , 2021, 12, 641905.	1.1	11
441	HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema. <i>Frontiers in Pharmacology</i> , 2021, 12, 671572.	1.6	8
442	Transcriptional signature in microglia associated with A β 2 plaque phagocytosis. <i>Nature Communications</i> , 2021, 12, 3015.	5.8	142
443	Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. <i>Frontiers in Immunology</i> , 2021, 12, 672737.	2.2	8
444	The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. <i>Pharmacological Reviews</i> , 2021, 73, 861-896.	7.1	18
445	Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. <i>Toxicological Sciences</i> , 2021, 183, 139-153.	1.4	9
446	The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 404-415.	2.7	24

#	ARTICLE	IF	CITATIONS
447	Polymorphisms in MHC class I molecules influence their interactions with components of the antigen processing and presentation pathway. <i>International Journal of Immunogenetics</i> , 2021, 48, 317-325.	0.8	6
448	Drug and Chemical Allergy: A Role for a Specific Naive T-Cell Repertoire?. <i>Frontiers in Immunology</i> , 2021, 12, 653102.	2.2	6
449	Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 607-615.	2.3	29
450	Drug hapten-specific T-cell activation: Current status and unanswered questions. <i>Proteomics</i> , 2021, 21, e2000267.	1.3	9
451	HLA class II immunopeptidomics reveals that co-inherited HLA allotypes within an extended haplotype can improve proteome coverage for immunosurveillance. <i>Proteomics</i> , 2021, 21, e2000160.	1.3	11
452	Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
454	Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity. <i>Communications Biology</i> , 2021, 4, 1137.	2.0	8
455	The pockets guide to HLA class I molecules. <i>Biochemical Society Transactions</i> , 2021, 49, 2319-2331.	1.6	46
456	HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, .	4.2	8
457	HLA Class-II-Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2412-2425.e2.	0.3	12
458	The PD1 inhibitory pathway and mature dendritic cells contribute to abacavir hypersensitivity in human leukocyte antigen transgenic PD1 knockout mice. <i>Toxicology</i> , 2021, 463, 152971.	2.0	0
459	Mechanisms of Hypersensitivity. , 2013, , 37-90.		3
460	Sequence-Based Typing of HLA: An Improved Group-Specific Full-Length Gene Sequencing Approach. <i>Methods in Molecular Biology</i> , 2014, 1109, 101-114.	0.4	33
461	Activation of the TCR Complex by Small Chemical Compounds. <i>Exs</i> , 2014, 104, 25-39.	1.4	5
462	Cutaneous Adverse Drug Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 2016, , 393-404.		1
463	MHC Molecules, T cell Receptors, Natural Killer Cell Receptors, and Viral Immunoevasins—Key Elements of Adaptive and Innate Immunity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1172, 21-62.	0.8	28
464	Genome-wide Study Identifies Association between HLA-B*55:01 and Self-Reported Penicillin Allergy. <i>American Journal of Human Genetics</i> , 2020, 107, 612-621.	2.6	34
465	Chemically Reactive versus Stable Drug Metabolites: Role in Adverse Drug Reactions. <i>RSC Drug Discovery Series</i> , 2015, , 202-226.	0.2	1

#	ARTICLE	IF	CITATIONS
466	Characterization of the Class I MHC Peptidome Resulting From DNCB Exposure of HaCaT Cells. <i>Toxicological Sciences</i> , 2021, 180, 136-147.	1.4	9
471	Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. <i>Journal of Clinical Investigation</i> , 2018, 128, 2746-2749.	3.9	13
472	Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. <i>Journal of Clinical Investigation</i> , 2018, 128, 1888-1902.	3.9	43
473	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018, 128, 1903-1912.	3.9	52
474	A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity. <i>Journal of Clinical Investigation</i> , 2018, 128, 2819-2832.	3.9	47
475	Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>F1000Research</i> , 2020, 9, 612.	0.8	67
476	<i>In silico</i> Analysis of Interactions between HLA-A*31:01 and carbamazepine-related Compounds. <i>Chem-Bio Informatics Journal</i> , 2016, 16, 5-8.	0.1	1
477	<i>In silico</i> Analysis of Interactions between Nevirapine-related Compounds, HLA-B*14:02 and T-cell Receptor. <i>Chem-Bio Informatics Journal</i> , 2016, 16, 9-12.	0.1	2
478	Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 17-27.	1.6	12
479	Abacavir Induced T Cell Reactivity from Drug Naïve Individuals Shares Features of Allo-Immune Responses. <i>PLoS ONE</i> , 2014, 9, e95339.	1.1	58
480	HLA Diversity in the 1000 Genomes Dataset. <i>PLoS ONE</i> , 2014, 9, e97282.	1.1	179
481	The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. <i>PLoS ONE</i> , 2015, 10, e0130928.	1.1	11
482	HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity. <i>PLoS ONE</i> , 2017, 12, e0184744.	1.1	13
483	Molecular Structure, Vibrational Spectra and Docking Studies of Abacavir by Density Functional Theory. <i>International Letters of Chemistry, Physics and Astronomy</i> , 0, 72, 9-27.	0.0	6
484	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. <i>Current Pharmaceutical Design</i> , 2019, 25, 3855-3871.	0.9	13
485	Molecular Docking to Identify Associations Between Drugs and Class I Human Leukocyte Antigens for Predicting Idiosyncratic Drug Reactions. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2015, 18, 296-304.	0.6	69
486	HLA-A, -B, -C, -DRB1, and -DQB1 Allele Lineages and Haplotype Frequencies among Saudis. <i>Immunology and Immunogenetics Insights</i> , 0, , 1.	1.0	5
487	Activating interactions of sulfanilamides with T cell receptors. <i>Open Journal of Immunology</i> , 2013, 03, 139-157.	0.5	19

#	ARTICLE	IF	CITATIONS
488	Pharmacogenomics and Rheumatological Practice. Journal of Clinical Rheumatology and Immunology, 0, , 1-12.	0.4	0
489	Advances and highlights in T and B cell responses to drug antigens. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1129-1138.	2.7	6
490	Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Human Genetics, 2022, 141, 1113-1136.	1.8	17
491	Small Molecule/HLA Complexes Alter the Cellular Proteomic Content. , 0, , .		1
492	Drug hypersensitivity. , 2013, , 564-577.		0
493	The Use of Proteomics to Dissect the Molecular Specificities of T Cells in Type 1 Diabetes. Journal of Diabetes & Metabolism, 2013, , .	0.2	0
494	Lymphocyte Transformation Test. , 2014, , 1-5.		2
496	Pathomechanism of SJS/TEN. Nishinohon Journal of Dermatology, 2015, 77, 337-339.	0.0	1
497	The Role of Pharmacogenomics in Individualized Medicine. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 93-112.	0.6	3
498	Pharmacogenetics of Adverse Drug Reactions. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-156.	0.6	0
499	HLA and Drug Hypersensitivity. , 2016, , 310-317.		0
501	Management of Severe Skin Eruptions. , 2017, , 759-763.		0
503	Drug-Induced Liver Disease. , 2017, , 204-216.		0
506	Pharmacogenomics: A New Approach for Preventing Severe Cutaneous Adverse Drug Reactions. , 2018, , 373-409.		2
509	Using Technology to Learn About Immunology of Cutaneous Adverse Drug Reactions. , 2019, , 67-74.		0
510	<i>In silico</i> analysis of interactions of flucloxacillin and its metabolites with HLA-B*57:01. Chem-Bio Informatics Journal, 2019, 19, 1-4.	0.1	0
513	An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3813-3828.	0.9	2
515	Mechanisms of Hypersensitivity. , 2021, , 59-137.		0

#	ARTICLE	IF	CITATIONS
516	Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. <i>Toxicological Sciences</i> , 2021, 179, 95-107.	1.4	2
517	Testing for drug hypersensitivity syndromes. <i>Clinical Biochemist Reviews</i> , 2013, 34, 15-38.	3.3	56
519	NEW STRATEGIES TO PREDICT AND PREVENT SERIOUS IMMUNOLOGICALLY MEDIATED ADVERSE DRUG REACTIONS. <i>Transactions of the American Clinical and Climatological Association</i> , 2018, 129, 74-87.	0.9	5
520	Lamotrigine and Stevens-Johnson Syndrome Prevention. <i>Psychopharmacology Bulletin</i> , 2021, 51, 96-114.	0.0	1
521	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. <i>Journal of Clinical Medicine</i> , 2021, 10, 5317.	1.0	3
522	Discovering new biology with drug-resistance alleles. <i>Nature Chemical Biology</i> , 2021, 17, 1219-1229.	3.9	11
525	Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis. <i>Current Pharmacology Reports</i> , 2022, 8, 79.	1.5	1
526	Unravelling the Proteomics of HLA-B*57:01+ Antigen Presenting Cells during Abacavir Medication. <i>Journal of Personalized Medicine</i> , 2022, 12, 40.	1.1	2
527	HLA variants associated with azathioprine-induced pancreatitis in patients with Crohn's disease. <i>Clinical and Translational Science</i> , 2022, , .	1.5	3
528	Functional and Structural Characteristics of HLA-B*13:01-Mediated Specific T Cells Reaction in Dapsone-Induced Drug Hypersensitivity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
529	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors. <i>Communications Biology</i> , 2022, 5, 133.	2.0	3
530	Editorial: The Immunology of Adverse Drug Reactions. <i>Frontiers in Immunology</i> , 2022, 13, 863414.	2.2	0
531	Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System. <i>Frontiers in Allergy</i> , 2022, 3, 827893.	1.2	6
532	Genetic predisposition and the variable course of infectious diseases. <i>Deutsches A&#x0308;rzteblatt International</i> , 2022, , .	0.6	4
533	HLA-G and the MHC Cusp Theory. <i>Frontiers in Immunology</i> , 2022, 13, 814967.	2.2	8
534	The emerging role of mass spectrometry-based proteomics in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 637-654.	21.5	110
535	Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects. <i>Biomedicines</i> , 2022, 10, 693.	1.4	1
536	MHC Class I Immunoepitome: Past, Present, and Future. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100230.	2.5	23

#	ARTICLE	IF	CITATIONS
537	In Vitro Monitoring of Human T Cell Responses to Skin Sensitizing Chemicals—A Systematic Review. <i>Cells</i> , 2022, 11, 83.	1.8	5
538	Pathogenesis of Autoimmune Hepatitis—Cellular and Molecular Mechanisms. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13578.	1.8	33
539	Palladium-Induced Temporal Internalization of MHC Class I Contributes to T Cell-Mediated Antigenicity. <i>Frontiers in Immunology</i> , 2021, 12, 736936.	2.2	0
540	Stevens—Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine. <i>Methods in Molecular Biology</i> , 2022, 2486, 37-54.	0.4	5
541	<i>In vitro</i> cell-based models of drug-induced hepatotoxicity screening: progress and limitation. <i>Drug Metabolism Reviews</i> , 2022, 54, 161-193.	1.5	5
542	Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics. <i>Frontiers in Pharmacology</i> , 2022, 13, 832048.	1.6	17
552	Progress in study on the association between HLA genetic variation and adverse drug reactions. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 404-413.	0.1	0
554	Unconventional modes of peptide—HLA-I presentation change the rules of TCR engagement. , 2022, 1, .		3
555	Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	2.0	3
556	Weak complex formation of adverse drug reaction-associated HLA B57, B58, and B15 molecules. <i>Toxicology in Vitro</i> , 2022, , 105383.	1.1	0
557	Carbamazepine-modified HLA-A*24:02-bound peptidome: Implication of CORO1A in skin rash. <i>International Immunopharmacology</i> , 2022, 109, 108804.	1.7	1
558	T cells discriminate between groups C1 and C2 HLA-C. <i>ELife</i> , 2022, 11, .	2.8	5
561	Genetic markers of drug hypersensitivity in pediatrics: current state and promise. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 715-728.	1.3	2
562	Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	9
563	Conjugation of human serum albumin and flucloxacillin provokes specific immune response in HLA-B*57:01 transgenic mice. <i>Immunology Letters</i> , 2022, 249, 5-11.	1.1	3
564	HLA—A*24:02 increase the risk of allopurinol—induced drug reaction with eosinophilia and systemic symptoms in HLA—B*58:01 carriers in a Korean population; a multicenter cross—sectional case—control study. <i>Clinical and Translational Allergy</i> , 2022, 12, .	1.4	2
565	Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1379-1390.	1.4	2
566	Consensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification. <i>Environmental Health Perspectives</i> , 2022, 130, .	2.8	19

#	ARTICLE	IF	CITATIONS
567	Pharmacogenetics of Cutaneous Adverse Drug Reactions. Updates in Clinical Dermatology, 2022, , 3-34.	0.1	0
568	Mechanisms of Drug Hypersensitivity. Updates in Clinical Dermatology, 2022, , 35-52.	0.1	0
569	Stevensâ€™Johnson Syndrome and Toxic Epidermal Necrolysis. Updates in Clinical Dermatology, 2022, , 111-126.	0.1	0
570	Modification of the HLA-A*24:02 Peptide Binding Pocket Enhances Cognate Peptide-Binding Capacity and Antigen-Specific T Cell Activation. Journal of Immunology, 2022, 209, 1481-1491.	0.4	0
571	Advances in the Understanding of Drug Hypersensitivity: 2012 Through 2022. Journal of Allergy and Clinical Immunology: in Practice, 2023, 11, 80-91.	2.0	2
572	Occupational health effect of TCE exposure: Experiment evidence of gene-environment interaction in hypersensitivity reaction. Chemico-Biological Interactions, 2022, 368, 110220.	1.7	2
573	Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report. Journal of Medical Case Reports, 2022, 16, .	0.4	3
575	Molecular Structure, Vibrational Spectra and Docking Studies of Abacavir by Density Functional Theory. International Letters of Chemistry, Physics and Astronomy, 0, 72, 9-27.	0.0	2
576	Risk factors and drugs that trigger the onset of Stevensâ€™Johnson syndrome and toxic epidermal necrolysis: A population-based cohort study using the Shizuoka Kokuho database. JAAD International, 2023, 11, 24-32.	1.1	6
577	CD1a promotes systemic manifestations of skin inflammation. Nature Communications, 2022, 13, .	5.8	9
578	Pathophysiology of drug hypersensitivity. British Journal of Clinical Pharmacology, 0, , .	1.1	3
579	Chemical- and Drug-Induced Allergic, Inflammatory, and Autoimmune Diseases Via Haptenation. Biology, 2023, 12, 123.	1.3	4
580	Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators. Biomedicines, 2023, 11, 177.	1.4	2
581	TCR_Explore: A novel webtool for T cell receptor repertoire analysis. Computational and Structural Biotechnology Journal, 2023, 21, 1272-1282.	1.9	4
582	Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 2023, 24, 350-362.	7.7	46
583	Endo-lysosomal assembly variations among human leukocyte antigen class I (HLA class I) allotypes. ELife, 0, 12, .	2.8	3
584	Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology, 2023, 151, 289-300.e4.	1.5	13
585	The impact of immunopeptidomics: From basic research to clinical implementation. Seminars in Immunology, 2023, 66, 101727.	2.7	17

#	ARTICLE	IF	CITATIONS
586	HLA-B*57:01/Carbamazepine-10,11-Epoxy Association Triggers Upregulation of the NF κ B and JAK/STAT Pathways. <i>Cells</i> , 2023, 12, 676.	1.8	1
587	Detection of Hepatic Drug Metabolite-Specific T-Cell Responses Using a Human Hepatocyte, Immune Cell Coculture System. <i>Chemical Research in Toxicology</i> , 2023, 36, 390-401.	1.7	4
588	Activation of Human CD8+ T Cells with Nitroso Dapsoneâ€“Modified HLA-B*13:01â€“Binding Peptides. <i>Journal of Immunology</i> , 2023, 210, 1031-1042.	0.4	2
589	Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review. <i>Genes</i> , 2023, 14, 689.	1.0	2
590	Drug Hypersensitivity. , 2023, , 630-647.		0